61 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
, even with every 4 weeks dosing, and no significant safety concerns. Taken together, the results further underscore rademikibart’s best-in-biologics … . Rademikibart was generally well tolerated with no unexpected safety signals.
oAnnounced positive long-term data from the China pivotal trial in patients
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
efficacy and safety in adult patients with moderate-to-severe persistent asthma.
This Phase 2b trial was a global, multicenter, randomized, double-blind … was started during the
worldwide COVID-19 pandemic and COVID-19 adverse events were noted across all treatment groups. No new safety signals were
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
in asthma control occurred early and was sustained through Week 24 for both doses of rademikibart
Safety results suggest rademikibart was generally … from T cell-driven research, announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
period) of its China pivotal trial evaluating rademikibart’s (formerly known as CBP-201) efficacy and safety in patients with moderate-to-severe atopic … at the end of the 52-week study.
Treatment with 300 mg Q2W and Q4W of rademikibart was generally well tolerated, and there were no new safety signals
6-K
EX-99.1
tz60ze 1bv0ew51
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
kf2qocwk
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
akgdpforiv
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
q8jv0e3llr3q
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
fjb75gr8s em7
23 Jun 23
House Lease Contract
4:31pm
6-K
EX-99.1
sqo4h8
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
1leduggbvspem1f
1 Jun 23
Current report (foreign)
4:24pm
6-K
oa68xpscg 1mj1t0fbh
1 Jun 23
Current report (foreign)
4:24pm
6-K
otcmnyw1
4 Oct 22
Current report (foreign)
7:16am
6-K
mmxkeqy jaxok
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
xkiewalty
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
cn31v6i
30 Aug 22
Current report (foreign)
4:01pm
6-K
vma50h j86x
11 Jul 22
Current report (foreign)
4:30pm
F-3/A
nxu1mte3qpf10
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm